Citations

Clear

3138 citation(s) found for "Smith, AM".

Patient-targeted education (ePRO-E) to increase ePRO intent within an Alliance clinical trial (A221805-SI1)
Smith, Elizabeth , Hillman, Shauna L., Scott, Mary R , Harlos, Elizabeth, Wills, Rachel, Loprinzi, Charles L. , Zahrieh, David M. , Lavoie Smith, Ellen M , Hillman, Shauna, Cho, Youmin , Wilson, Christina M.

Mayo Clinic

JNCI Cancer Spectrum | January 17, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/jncics/pkae002 | PMID 38230706 Get It

Abstract Background The Patient Cloud ePRO app was adopted by the National Cancer Institute National Clinical Trials Network (NCTN) to facilitate capturing electronic patient-reported (ePRO) outcome data, but use has been low. The study objectives were to test whether a patient-targeted ePRO educational resource (ePRO-E) would increase ePRO intent (number of users) and improve data quality (high quality: ≥80% of the required surveys submitted) within an ongoing NCTN study. Methods The ePRO-E intervention, a patient-targeted educational resource (written material and 6-minute animated YouTube video), was designed to address ePRO barriers. ePRO intent and data quality were compared between 2 groups (N = 69): a historical control group and a prospectively recruited intervention group exposed to ePRO-E. Covariates included technology attitudes, age, sex, education, socioeconomic status, and comorbidity. Results Intervention group ePRO intent (78.8%) was statistically significantly higher than historical control group intent (47.1%) (P = .03). Patients choosing ePRO versus paper surveys had more positive and higher technology attitudes scores (P = .03). The odds of choosing ePRO were 4.7 times higher (95% Confidence Interval [CI] = 1.2 to 17.8) (P = .02) among intervention group patients and 5.2 times higher (95% CI = 1.3 to 21.6) (P = .02) among patients with high technology attitudes scores, after controlling for covariates. However, the 80% submission rate (percentage submitting ≥80% of required surveys) in the ePRO group (30.6%) was statistically significantly lower than in the paper group (57.9%) (P = .05). Conclusions ePRO-E exposure increased ePRO intent. High technology attitudes scores were associated with ePRO selection. Since the ePRO survey submission rate was low, additional strategies are needed to promote high-quality data submission.
Calprotectin Impairs Platelet Survival in Patients With Primary Antiphospholipid Syndrome
Hoy, Claire K., NaveenKumar, Somanathapura K. , Navaz, Sherwin, Sugur, Kavya, Yalavarthi, Srilakshmi , Sarosh, Cyrus , Smith, Tristin , Kmeťová, Katarína , Chong, Emily , Peters, Noah F., Rysenga, Christine E. , Norman, Gary L. , Figueroa‐Parra, Gabriel , Nelson, Dava, Girard, Jennifer , Ahmed, Asra, Schaefer, Jordan K. , Crowson, Cynthia S. , Zuo, Yu , Kahlenberg, J Michelle , Crowson, CS , Duarte-García, Alí , Zuo, Yu , Figueroa-Parra, Gabriel , Sarosh, Cyrus , Schaefer, Jordan K , Kmetova, Katarina , Gudjonsson, Johann E , Kahlenberg, J. Michelle , Madison, Jacqueline A. , Knight, Jason S , Duarte‐García, Alí

Mayo Clinic

Arthritis & Rheumatology | January 16, 2024 | Volume: 76 | Issue: 6 | Pages: 928-935

10.1002/art.42801 | PMID 38225923 Get It

ObjectiveWhile thrombosis and pregnancy loss are the best‐known clinical features of antiphospholipid syndrome (APS), many patients also exhibit “extra‐criteria” manifestations, such as thrombocytopenia. The mechanisms that drive APS thrombocytopenia are not completely understood, and no clinical biomarkers are available for predicting antiphospholipid antibody (aPL)–mediated thrombocytopenia. Calprotectin is a heterodimer of S100A8 and S100A9 that is abundant in the neutrophil cytoplasm and released upon proinflammatory neutrophil activation. Here, we sought to evaluate the presence, clinical associations, and potential mechanistic roles of circulating calprotectin in a cohort of primary APS and aPL‐positive patients.MethodsLevels of circulating calprotectin were determined in plasma by the QUANTA Flash chemiluminescent assay. A viability dye‐based platelet assay was used to assess the potential impact of calprotectin on aPL‐mediated thrombocytopenia.ResultsCirculating calprotectin was measured in 112 patients with primary APS and 30 aPL‐positive (without APS criteria manifestations or lupus) patients as compared to patients with lupus (without APS), patients with unprovoked venous thrombosis (without aPL), and healthy controls. Levels of calprotectin were higher in patients with primary APS and aPL‐positive patients compared to healthy controls. After adjustment for age and sex, calprotectin level correlated positively with absolute neutrophil count (r = 0.41, P < 0.001), positively with C‐reactive protein level (r = 0.34, P = 0.002), and negatively with platelet count (r = −0.24, P = 0.004). Mechanistically, we found that calprotectin provoked aPL‐mediated thrombocytopenia by engaging platelet surface toll‐like receptor 4 and activating the NLRP3‐inflammasome, thereby reducing platelet viability in a caspase‐1‐dependent manner.ConclusionThese data suggest that calprotectin has the potential to be a functional biomarker and a new therapeutic target for APS thrombocytopenia.image
Assessing cardiovascular disease risk in women with a history of hypertensive disorders of pregnancy: A guidance paper for studies using administrative data
Johnston, Amy , Smith, Graeme N. , Coutinho, Thais , Smith, Graeme N , Tanuseputro, Peter , Edwards, Jodi D.

Mayo Clinic

Paediatric and Perinatal Epidemiology | January 15, 2024 | Volume: 38 | Issue: 3 | Pages: 254-267

10.1111/ppe.13043 | PMID 38220144 Get It

AbstractBackgroundHypertensive disorders of pregnancy (HDP) are a major cause of maternal morbidity and mortality, and their association with increased cardiovascular disease (CVD) risk represents a major public health concern. However, assessing CVD risk in women with a history of these conditions presents unique challenges, especially when studies are carried out using routinely collected data.ObjectivesTo summarise and describe key challenges related to the design and conduct of administrative studies assessing CVD risk in women with a history of HDP and provide concrete recommendations for addressing them in future research.MethodsThis is a methodological guidance paper.ResultsSeveral conceptual and methodological factors related to the data‐generating mechanism and study conceptualisation, design/data management and analysis, as well as the interpretation and reporting of study findings should be considered and addressed when designing and carrying out administrative studies on this topic. Researchers should develop an a priori conceptual framework within which the research question is articulated, important study variables are identified and their interrelationships are carefully considered.ConclusionsTo advance our understanding of CVD risk in women with a history of HDP, future studies should carefully consider and address the conceptual and methodological considerations outlined in this guidance paper. In highlighting these challenges, and providing specific recommendations for how to address them, our goal is to improve the quality of research carried out on this topic.
Conjunctival Biopsy of a Patient With Mpox
Tran, Meagan , Gonzalez, Valeria , Patel, Dharmendra , Shusko, Alexander , McCullough, Ann E. , Shah, Ami, McCullough, Ann, Gonzalez, Valeria V , Shah, Ami A. , Patel, Dharmendra

Mayo Clinic

JAMA Ophthalmology | January 11, 2024 | Volume: 142 | Issue: 2 | Pages: 157

10.1001/jamaophthalmol.2023.5780 | PMID 38206632 Get It

This case report describes a conjunctival biopsy of a patient with mpox infection.
Serum lactate and mean arterial pressure thresholds in patients with cirrhosis and septic shock
Smith, Thomas N. , Choi, Chansong , Rattan, Puru , Serafim, Laura Piccolo, Kassmeyer, Blake A., Lennon, Ryan J. , Gajic, Ognjen , Olson, Jody C. , Kamath, Patrick S. , Moraes, Alice Gallo de , Piccolo Serafim, Laura, Simonetto, Douglas A , Choi, Chansong , Gallo de Moraes, Alice , Gajic, Ognjen , Simonetto, Douglas A.

Mayo Clinic

Hepatology Communications | January 5, 2024 | Volume: 8 | Issue: 1 | Pages: No page available

10.1097/hc9.0000000000000353 | PMID 38180993 Get It

Background: The Sepsis-3 guidelines have incorporated serum lactate levels of >2 mmol/L in septic shock definition to account for higher observed mortality. Further evidence is needed to support this threshold in cirrhosis, as well as target mean arterial pressure (MAP) during resuscitation. Methods: This observational cohort study investigated the association between initial serum lactate and resuscitation MAP levels on in-hospital mortality in patients with and without cirrhosis. Patients admitted to the intensive care unit for the treatment of septic shock between 2006 and 2021 in a quaternary academic center were included. Patients with cirrhosis documented on imaging and International Classification of Disease codes (n=595) were compared to patients without cirrhosis (n=575). The association of intensive care unit admission lactate levels and median 2-hour MAP with in-hospital mortality and the need for continuous renal replacement therapy was assessed. The association between median 24-hour MAP and in-hospital mortality was analyzed post hoc. Results: Within the cirrhosis group, admission lactate levels of 2–4 and >4 mmol/L were associated with increased in-hospital mortality compared to lactate <2 mmol/L [adjusted odds ratio (aOR): 1.69, CI: 1.03–2.81, aOR: 4.02, CI: 2.53–6.52]. Median 24-hour MAP 60–65 and <60 mm Hg were also associated with increased in-hospital mortality compared with MAP >65 mm Hg (aOR: 2.84, CI: 1.64–4.92 and aOR: 7.34, CI: 3.17–18.76). In the noncirrhosis group, associations with in-hospital mortality were weaker for lactate 2–4 and >4 mmol/L (aOR: 1.32, CI: 0.77–2.27 and aOR: 2.25, CI: 1.40–3.67) and median 24-hour MAP 60–65 and <60 mm Hg (aOR: 1.70, CI: 0.65–4.14 and aOR: 4.41, CI: 0.79–29.38). Conclusions: These findings support utilizing lactate >2 mmol/L in the definition of septic shock, as well as a target MAP of >65 mm Hg during resuscitation in patients with cirrhosis.
Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors
Smith, Katherine E. , Markovic, Svetomir N. , Smith, Katherine E R

Mayo Clinic

Clinical Chemistry | January 4, 2024 | Volume: 70 | Issue: 1 | Pages: 25-26

10.1093/clinchem/hvad128 | PMID 38175581 Get It

Virology—the path forward
Grönvall, Gigi Kwik , Lowen, Anice C. , Goodrum, Felicia , Alwine, James C. , Andersen, Kristian G. , Anthony, Simon J. , Baines, Joel D. , Banerjee, Arinjay , Broadbent, Andrew J. , Brooke, Christopher B. , Campos, Samuel K. , Caposio, Patrizia , Chan, Gary C. , Collins-McMillen, Donna , Connell, Nancy , Damania, Blossom , Daugherty, Matthew D. , Dermody, Terence S. , Galloway, Denise A. , Hartman, Amy L. , Hogue, Brenda G. , Jung, Jae U. , Karst, Stephanie M. , Laimins, Lou, Landais, Igor, Lindenbach, Brett D. , Luftig, Micah A. , Mehle, Andrew , Moscona, Anne , Münger, Karl , Nikolich‐Žugich, Janko , Popescu, Saskia , Racaniello, Vincent R. , Rice, Charles M. , Runstadler, Jonathan A. , Sapp, Martin , Scott, Rona S. , Streblow, Daniel N. , Doorslaer, Koenraad Van , White, Elizabeth , White, Timothy M. , Worobey, Michael , Yamaoka, Satoko , Rasmussen, Angela L , Gronvall, Gigi K , Lowen, Anice C , Goodrum, Felicia , Baines, Joel , Banerjee, Arinjay , Broadbent, Andrew J , Brooke, Christopher B , Campos, Samuel K , Caposio, Patrizia , Casadevall, Arturo , Chan, Gary C , Cliffe, Anna R , Damania, Blossom , Dermody, Terence S , DiMaio, Daniel , Duprex, W Paul , Greninger, Alexander L , Hartman, Amy L , Horner, Stacy M , Jung, Jae U , Kamil, Jeremy P , Laimins, Lou , Lakdawala, Seema S , Letko, Michael , Liu, Shan-Lu , Luftig, Micah , McFadden, Grant , Mehle, Andrew , Moscona, Anne , Munger, Joshua , Murphy, Eain , O'Connor, Christine M , Pekosz, Andrew , Permar, Sallie R , Pfeiffer, Julie K , Purdy, John G , Runstadler, Jonathan A , Sapp, Martin J , Scott, Rona S , Smith, Gregory A , Tibbetts, Scott A , Toth, Zsolt , Weiss, Susan R , White, Elizabeth A , Wobus, Christiane E , Yurochko, Andrew , Nikolich, Janko Z , Casadevall, Arturo , Debbink, Kari M. , Duprex, W. Paul , Emerman, Michael , Garry, Robert F. , Goldstein, Stephen A. , Greninger, Alexander L. , Hotez, Peter Jay , Morrison, Juliet , Mühlberger, Elke , Neufeldt, Christopher John , O’Connor, Christine M. , Permar, Sallie R. , Sorrell, Erin M. , Speranza, Emily E. , Wobus, Christiane E.

Mayo Clinic

Journal of Virology | January 3, 2024 | Volume: 98 | Issue: 1 | Pages: No page available

10.1128/jvi.01791-23 | PMID 38168672 Get It

ABSTRACT In the United States (US), biosafety and biosecurity oversight of research on viruses is being reappraised. Safety in virology research is paramount and oversight frameworks should be reviewed periodically. Changes should be made with care, however, to avoid impeding science that is essential for rapidly reducing and responding to pandemic threats as well as addressing more common challenges caused by infectious diseases. Decades of research uniquely positioned the US to be able to respond to the COVID-19 crisis with astounding speed, delivering life-saving vaccines within a year of identifying the virus. We should embolden and empower this strength, which is a vital part of protecting the health, economy, and security of US citizens. Herein, we offer our perspectives on priorities for revised rules governing virology research in the US.
CORR Insights®: Does A Hinged Operating Table Facilitate Sagittal Correction in Transforaminal Lumbar Interbody Fusion With Smith-Peterson Osteotomy? A Radiographic Analysis
Nassr, Ahmad

Mayo Clinic

Clinical Orthopaedics & Related Research | January 2, 2024 | Volume: 482 | Issue: 6 | Pages: 1071-1073

10.1097/corr.0000000000002956 | PMID 38165280 Get It

Practice Readiness? Trends in Chief Resident Year Training Experience Across 13 Residency Programs
Corey, Zachary , Lehman, Erik , Lemack, Gary E. , Clifton, Marisa , Atiemo, Humphrey , Sorensen, Mathew D., Smith, Ryan P. , Buckley, Jill C. , Thompson, Houston, Badalato, Gina M., Wallen, Eric, Klausner, Adam P. , Mehta, Akanksha , Lee, Richard S. , Breyer, Benjamin N. , Raman, Jay D.

Mayo Clinic

Urology Practice | December 29, 2023 | Volume: 11 | Issue: 2 | Pages: 430-438

10.1097/upj.0000000000000494 | PMID 38156717 Get It

Adenomyoepithelioma of the Breast: Radiologic-Pathologic Correlation and Management
Smith, Katherine , Solanki, Malvika , Glazebrook, Katrina N. , Smith, Katherine A , Solanki, Malvika H

Mayo Clinic

Journal of Breast Imaging | December 28, 2023 | Volume: 6 | Issue: 1 | Pages: 64-71

10.1093/jbi/wbad098 | PMID 38153758 Get It

Abstract Adenomyoepithelioma (AME) is a rare, usually benign breast neoplasm with low potential for malignant transformation. Imaging features are nonspecific and overlap with other benign and malignant breast lesions. On mammography, AME most often presents as a mass, usually oval in shape, with variable reported margins. Less commonly, AME can present mammographically as an asymmetry or can be mammographically occult. Associated calcifications are uncommon. On US, AME is usually seen as a hypoechoic oval mass, but it can also manifest as a complex cystic and solid mass. On US, the majority of AME have noncircumscribed margins (indistinct, angular, or microlobulated). Internal vascularity is usually present, and posterior enhancement can be seen. Although there is limited literature on MRI features, the most frequent finding is an irregular mass with washout kinetics; T2 hyperintensity can be observed. These nonspecific and often suspicious imaging features usually merit biopsy. On histologic analysis, AME is characterized by a biphasic proliferation of myoepithelial and epithelial cells. Pathologic diagnosis can be difficult due to the variety of histologic features of AME and heterogeneity in these tumors, especially when sampling is limited, such as in core needle biopsies. Wide local surgical excision of AME is recommended due to potential for recurrence and malignant transformation.